Inogen NASDAQ: INGN executives used a fireside chat at the 25th Annual Needham Healthcare Conference to outline the company’s strategic priorities, discuss its product expansion beyond portable oxygen concentrators, and address recent financial trends. The session was hosted by Needham & Company senior analyst Mike Matson and featured President and CEO Kevin Smith and newly appointed CFO Jason Richardson.
New CFO and leadership additions
Richardson, speaking publicly for the first time since joining the company, said he brings 25 years of MedTech experience, including leadership roles at Hillrom and Baxter. He most recently served as CFO of Baxter’s Health Systems and Technology segment and said his background includes operational and integration work as well as exposure to a respiratory care franchise at Hillrom.
Richardson said he joined Inogen for three primary reasons: the people he met across leadership and the board, the company’s recent performance—citing “two straight years” of mid-single-digit growth and “pretty significant improvement in adjusted EBITDA”—and what he described as an “inflection point” opportunity to accelerate growth and margin expansion.
Smith also highlighted additional senior hires, including a chief marketing officer and a vice president of U.S. business-to-business sales. He described the moves as a “deliberate realignment” to support priorities such as driving top-line growth, advancing profitability, and expanding the innovation pipeline. Smith said the marketing function existed previously but is being elevated to a more strategic role reporting directly to him.
Supply chain and cost exposure
Asked about potential impacts from elevated oil prices, Smith said Inogen has seen “limited impact” so far. He noted the company uses resin and plastic components in its portable oxygen concentrators and has supply arrangements that provide protection. He added that Inogen does not rely heavily on air freight or overnight shipping, reducing exposure relative to some peers, though prolonged higher oil prices could have future effects.
Product expansion: Voxi 5, Simeox, and Aurora masks
Smith said the company’s stationary concentrator, Voxi 5, has received “exceptional” feedback and acceptance. He said Inogen worked with UL and made improvements to the original design, positioning Voxi 5 for both the B2B channel and direct-to-consumer (DTC). Smith framed the product as a portfolio expansion that targets the same patient population as portable oxygen concentrators, noting that patients often need both stationary and portable systems at different points in therapy.
On Inogen’s relationship with Yuwell and plans to sell portable oxygen concentrators in China, Smith said the effort remains in the regulatory process and the company has not provided specific timing. He described China as an attractive market due to COPD prevalence and environmental factors, adding that Inogen plans to enter as a “premium play.” He said the main hurdle is regulatory approval, including required documentation and testing.
Smith also discussed Simeox, which Inogen is positioning as an airway clearance therapy for non-cystic fibrosis bronchiectasis. He said the product is marketed in European countries today and compared its intended mucus-clearing benefits to vest-based therapies, but via a handheld tube device that applies waveforms. In the U.S., he said Inogen has FDA clearance and is working toward reimbursement through CMS, which requires clinical trials. Smith said enrollment is active for the first trial, but the company has not guided to a timeline. He characterized Simeox as expanding Inogen’s addressable market by about $500 million and described the economics as a “razor/razor blade model” with “attractive gross margins.”
Inogen is also entering the CPAP mask market with its Aurora family. Smith cited a $2.2 billion U.S. total addressable market for CPAP masks and said there is about a 20% to 30% overlap with Inogen’s core COPD patient population. He said Inogen is initially focusing on new patient setups, which he estimated conservatively at about $400 million, because existing patients tend to stick with masks they already tolerate. Smith said Inogen conducted clinical work across three cohorts and was encouraged by patient preference data; he added a publication is expected to be released following presentation at a sleep conference.
Connectivity and the digital ecosystem
Smith said all Inogen portable oxygen concentrators already have Bluetooth connectivity, can connect to smartphones, and work with an app the company has developed for patients. He said the company is adding more features over time to support patients, physicians, and B2B customers. For B2B providers, he said connectivity enables visibility into device health and predictive service needs, which can support technician routing and reduce emergency service calls.
Channel mix, financial trends, and capital allocation
Matson asked about declines in Inogen’s DTC rental and consumer sales businesses. Smith said overall demand is increasing and that unit volume has risen “a little more than 20%” when looking at 2025, but channel dynamics have shifted. He said HMEs are now providing more patients with portable oxygen concentrators at therapy start—about 60% compared with 30% to 40% a few years ago—reducing the pool of patients who might self-advocate and buy or rent directly from Inogen after being offered oxygen tanks.
On the B2B side, Smith said the market still has room to grow, noting roughly 40% of new starts still receive tanks rather than portable concentrators. He also emphasized Inogen’s differentiation on total cost of ownership, including serviceability, patient-changeable sieve beds, and an “eight-year useful life versus a five-year useful life,” which he said can help HMEs depreciate devices over a longer period. He added that Inogen is investing in evidence generation, including clinical trials, a fellowship program planned for later in the year, and physician education with key opinion leaders to avoid commoditization.
Discussing recent financial results, Smith attributed the moderation in reported revenue growth and the decline in 2025 gross margin largely to channel and customer mix, with more volume coming from B2B customers that receive volume-based discounts. Richardson added that product launches are expected to support margin expansion going forward, and he noted that adjusted EBITDA improved “substantially” despite the margin pressure.
Smith said newer products such as Aurora masks and Simeox have margin profiles that are “accretive to the blended margin,” and he said the company is committed to ensuring new launches improve blended margins.
On cash flow, Smith said 2025 operating cash flow was affected by several items, including a $9.8 million earn-out payment related to the PhysioAssist acquisition, higher year-end accounts receivable tied to late-year shipments, and certain one-time staffing costs such as severance related to rightsizing.
Smith also discussed capital allocation, saying the company believes its stock is undervalued. He noted the board authorized a $30 million share repurchase program on Feb. 24 and said Inogen intends to execute buybacks over the next couple of years. Richardson said the company has already begun repurchasing shares and plans to provide an update on the next earnings release.
Regarding M&A, Smith said Inogen’s immediate focus is executing on current launches, but the company continues to evaluate opportunities and would act if it finds a target that it believes would increase shareholder value.
About Inogen NASDAQ: INGN
Inogen, Inc NASDAQ: INGN is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company's core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen's offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.
Inogen's flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
